Neurotech Pharmaceuticals

Neurotech Pharmaceuticals is a pioneering biotech company that has successfully developed and commercialized the first-ever therapy for Macular Telangiectasia Type 2 (MacTel), a previously untreatable retinal disease. The company's proprietary Encapsulated Cell Therapy platform enables long-term, localized delivery of therapeutic proteins like Ciliary Neurotrophic Factor (CNTF) to protect photoreceptors. Having secured FDA approval and a permanent J-Code for reimbursement in 2025, Neurotech has transitioned to a commercial-stage company, positioning it to address a significant unmet need in ophthalmology and potentially expand its platform to other chronic eye diseases.

Encapsulated Cell Therapy (ECT) platform: an implantable device containing genetically engineered cells that secrete therapeutic proteins (e.g., CNTF) locally in the eye for sustained, long-term delivery.

For MacTel, Neurotech faces no direct pharmacological competition, owning a complete monopoly. However, in the broader retinal disease space, it would compete with large pharmaceutical companies (e.g., Roche/Genentech, Regeneron, Apellis) and biotechs developing intravitreal injections, gene therapies, and other implants for conditions like geographic atrophy and diabetic macular edema.